• Mashup Score: 1
    American Diabetes Association Releases a Guideline Update in NAFLD (Non-Alcoholic Fatty Liver Disease) and Diabetes | ADA - 10 month(s) ago

    New guidelines include recommendations for the detection and management of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in people with diabetes Today, the American Diabetes Association® (ADA) published updates in the Standards of Care in Diabetes—2023 (Standards of Care) based on the latest scientific research and clinical trials. Liver disease affects up to 70% of…

    Source: diabetes.org
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ADA_DiabetesPro
      ADA_DiabetesPro

      #BreakingNews: The ADA published updates in the Standards of Care in Diabetes—2023. Updates include recommendations for the detection & management of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in people with #diabetes. https://t.co/T1HdRrRMJa https://t.co/nt9FHUNqfE

  • Mashup Score: 0
    Minutia, Oregon Health & Sciences University and Go Pen Win First-Ever American Diabetes Association Innovation Challenge | ADA - 10 month(s) ago

    Reality show style competition showcases novel diabetes business ideas with potential funders as part of ADA 83rd Scientific Sessions Today, the American Diabetes Association® (ADA) announced the winner of its inaugural pitch competition at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA. The first-ever Innovation Challenge highlighted six business…

    Source: diabetes.org
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ADA_DiabetesPro
      ADA_DiabetesPro

      #BreakingNews: The ADA announced the winners of its inaugural pitch competition at #ADA2023. The winners: Minutia, Oregon Health & Science University, and GO-Pen ApS presented three impactful solutions to a variety of diabetes challenges. https://t.co/wd1LUa0x8z. https://t.co/GVoT2IR4Ag

  • Mashup Score: 2
    Behavioral Health Interventions Positively Impact Adults and Youth Experiencing Diabetes Distress  | ADA - 11 month(s) ago

    Findings Indicate Improvements in Mental and Physical Health as well as a Reduction in Healthcare Costs For People Living with Type 1 Diabetes Results from two studies evaluating the impact of mental health support for diabetes patients found significant benefits in patient outcomes were presented today at  the 83rd Scientific Sessions of the American Diabetes Association® (ADA) in San Diego,…

    Source: diabetes.org
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AmDiabetesAssn
      AmDiabetesAssn

      #BreakingNews: Results from two studies evaluating the impact of mental health support for diabetes patients found significant benefits in patient outcomes were presented today at #ADA2023. Learn more at https://t.co/euLjryz9Bm. https://t.co/HKLBsmTJlv

    • Profile photo of ADA_DiabetesPro
      ADA_DiabetesPro

      #BreakingNews: Results from two studies evaluating the impact of mental health support for diabetes patients found significant benefits in patient outcomes were presented today at #ADA2023. Learn more at https://t.co/iCrMN33l3g. https://t.co/8CB0bSIX6c

  • Mashup Score: 1
    Cholesterol Lowering Drug Shown to Cut Major Heart-Related Events and Risk of Death from Heart Disease by One-Third for Statin-Intolerant Patients | ADA - 11 month(s) ago

    First-of-its-Kind Data Underscore Importance of Early Use of Drug Therapy as a Primary Prevention,  Especially for Those Living with DiabetesToday, a new trial revealed data on the effects of bempedoic acid – a non-statin cholesterol-lowering drug – on cardiovascular outcomes, demonstrating that patients with risk factors for coronary artery disease (CAD) and high cholesterol, particularly those…

    Source: diabetes.org
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AmDiabetesAssn
      AmDiabetesAssn

      #BreakingNews: Latest trial results on bempedoic acid - a non-statin cholesterol-lowering drug, show that it's effective in reducing cardiovascular risks, especially in people with #diabetes! Learn more at https://t.co/SC7evC5jzn. #ADA2023 https://t.co/xozVmX6Frj

    • Profile photo of ADA_DiabetesPro
      ADA_DiabetesPro

      #BreakingNews: Latest trial results on bempedoic acid - a non-statin cholesterol-lowering drug, show that it's effective in reducing cardiovascular risks, especially in people with #diabetes! Learn more at https://t.co/m9rRcdECfs. #ADA2023 https://t.co/hCXf63eE0i

  • Mashup Score: 1
    Childhood Diabetes Screening Shown to Predict Future Diabetes-Related Complications | ADA - 11 month(s) ago

    New Study Highlights the Importance of Early Glycemic Screening in High-Risk Children to Prevent Long-Term Health Complications from Diabetes New research from the National Institutes of Health (NIH) found that blood glucose levels obtained at childhood examinations predicted future diabetes related complications such as kidney disease (nephropathy) and eye disease (retinopathy). The findings…

    Source: diabetes.org
    Categories: Endocrinology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ADA_DiabetesPro
      ADA_DiabetesPro

      #BreakingNews: New research from the @NIH found that blood glucose levels obtained at childhood examinations predicted future diabetes related complications such as kidney disease (nephropathy) and eye disease (retinopathy). https://t.co/MCuDypdeCB #ADA2023 https://t.co/YQtTbzl7MW

  • Mashup Score: 1
    Wolters Kluwer Health - 11 month(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Source: lww.com
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of NeurologyToday
      NeurologyToday

      The @US_FDA has approved a new gene therapy from Sarepta Therapeutics, SRP-9001 (delandistrogene moxeparvovec), for Duchenne #MuscularDystrophy: https://t.co/bHYPsNVSq2 #neurotwitter #BreakingNews @AANMember https://t.co/qbpag55t21

Load More